THERAPEX Co., Ltd
Therapex develops patient-specific anti-cancer drugs through molecular testing that targets cancer-causing proteins and mutations, focusing on treatment-resistant solid tumors. The company employs advanced drug design techniques, including PROTAC technology, to create therapies for patients with limited treatment options.
- Biotechnology
Funding
Founders
Founder details are not available yet.
Product
Problem
Many solid tumors develop resistance to standard treatments, leaving patients with limited options and a poor prognosis. Current therapies often fail to address the underlying molecular drivers of cancer growth and drug resistance, leading to disease progression.
Solution
Therapex is developing patient-specific anti-cancer drugs by targeting cancer-causing proteins and mutations identified through molecular testing. The company focuses on treatment-resistant solid tumors and employs advanced drug design techniques, including PROTAC (PROteolysis TArgeting Chimera) technology, to create innovative therapies. These therapies aim to overcome drug resistance by directly degrading disease-causing proteins, offering new hope for patients with limited treatment alternatives.
Target Audience
The primary target audience includes patients with treatment-resistant solid tumors, particularly non-small cell lung cancer, and the oncologists treating these patients.
Features
- Development of 4th generation EGFR inhibitors to overcome resistance in non-small cell lung cancer (NSCLC)
- PROTAC technology platform for targeted protein degradation of "undruggable" proteins
- Focus on overcoming resistance to existing therapies like Tagrisso in EGFR-mutated NSCLC
- Preclinical development of novel immunotherapies for solid tumors
- ADC (Antibody-Drug Conjugate) technology development for targeted drug delivery
- In-silico modeling for rapid lead discovery